CoChat

New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation

Open access
Tan, Justin L., Li, Feng, Yeo, Joanna Z., Yong, Kol Jia, Bassal, Mahmoud A., Ng, Guo Hao, Lee, May Yin, Leong, Chung Yan, Tan, Hong Kee, Wu, Chan-shuo, Liu, Bee Hui, Chan, Tim H., Tan, Zi Hui, Chan, Yun Shen, Wang, Siyu, Lim, Zhi Han, Toh, Tan Boon, Hooi, Lissa, Low, Kia Ngee, Ma, Siming, Kong, Nikki R., Stein, Alicia J., Wu, Yue, Thangavelu, Matan T., Suzuki, Atsushi, Periyasamy, Giridharan, Asara, John M., Dan, Yock Young, Bonney, Glenn K., Chow, Edward K., Lu, Guo-Dong, Ng, Huck Hui, Kanagasundaram, Yoganathan, Ng, Siew Bee, Tam, Wai Leong, Tenen, Daniel G., Chai, Li · 2019 · Gastroenterology
Cited by 64

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

Background and Aims: Some oncogenes encode transcription factors, but few drugs have been successfully developed to block their activity specifically in cancer cells. The transcription factor SALL4 is aberrantly expressed in solid tumor and leukemia cells. We developed a screen to identify compounds that reduce the viability of liver cancer cells that express high levels of SALL4 and we investigated their mechanisms. Methods: We developed a stringent high-throughput screening platform comprising unmodified SNU-387 and SNU-398 liver cancer cell lines and SNU-387 cell lines engineered to express low and high levels of SALL4. We screened 1597 pharmacologically active small molecules and 21,575 natural product extracts from plant, bacteria, and fungal sources for those that selectively reduce the viability of cells with high levels of SALL4 (SALL4hi cells). We compared gene expression patterns of SALL4hi cells vs SALL4-knockdown cells using RNA-seq and real-time PCR analyses. Xenograft tumors were grown in NOD/SCID gamma mice from SALL4hi SNU-398 or HCC26.1 cells or from SALL4lo PDX cells; mice were given injections of identified compounds or sorafenib and the effects on tumor growth were measured. Results: Our screen identified 1 small molecule (PI-103) and 4 natural compound analogues (oligomycin, efrapeptin, antimycin, and leucinostatin) that selectively reduced viability of SALL4hi cells. We performed validation studies, and 4 of these compounds were found to inhibit oxidative phosphorylation. The ATP synthase inhibitor oligomycin reduced the viability of SALL4hi hepatocellular carcinoma and non-small–cell lung cancer cell lines with minimal effects on SALL4lo cells. Oligomycin also reduced the growth of xenograft tumors grown from SALL4hi SNU-398 or HCC26.1 cells, to a greater extent than sorafenib, but oligomycin had little effect on tumors grown from SALL4lo PDX cells. Oligomycin was not toxic to mice. Analyses of chromatin immunoprecipitation sequencing data revealed that SALL4 binds approximately 50% of mitochondrial genes, including many oxidative phosphorylation genes, to activate their transcription. In comparing SALL4hi and SALL4-knockdown cells, we found SALL4 to increase oxidative phosphorylation, oxygen consumption rate, mitochondrial membrane potential, and utilization of oxidative phosphorylation-related metabolites to generate ATP. Conclusions: In a screen for compounds that reduce the viability of cells that express high levels of the transcription factor SALL4, we identified inhibitors of oxidative phosphorylation, which slowed the growth of xenograft tumors from SALL4hi cells in mice. SALL4 activates transcription of genes that regulate oxidative phosphorylation to increase oxygen consumption, mitochondrial membrane potential, and ATP generation in cancer cells. Inhibitors of oxidative phosphorylation might be used for treatment of liver tumors with high levels of SALL4.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2019.08.022

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 64

Metadata

Authors
Tan, J. L., Li, F., Yeo, J. Z., Yong, K. J., Bassal, M. A., Ng, G. H., Lee, M. Y., Leong, C. Y., Tan, H. K., Wu, C.-S., Liu, B. H., Chan, T. H., Tan, Z. H., Chan, Y. S., Wang, S., Lim, Z. H., Toh, T. B., Hooi, L., Low, K. N., Ma, S., Kong, N. R., Stein, A. J., Wu, Y., Thangavelu, M. T., Suzuki, A., Periyasamy, G., Asara, J. M., Dan, Y. Y., Bonney, G. K., Chow, E. K., Lu, G.-D., Ng, H. H., Kanagasundaram, Y., Ng, S. B., Tam, W. L., Tenen, D. G., & Chai, L.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2019-12
Volume
157
Issue
6
Pages
1615-1629.e17
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2969431868
Cited by
64
References
20
FWCI
2.00
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation. https://app.cochat.ai/papers/10.1053/j.gastro.2019.08.022
The paper
Tan, J. L., Li, F., Yeo, J. Z., Yong, K. J., Bassal, M. A., Ng, G. H., Lee, M. Y., Leong, C. Y., Tan, H. K., Wu, C.-S., Liu, B. H., Chan, T. H., Tan, Z. H., Chan, Y. S., Wang, S., Lim, Z. H., Toh, T. B., Hooi, L., Low, K. N., . . . Chai, L. (2019). New High-Throughput Screening Identifies Compounds That Reduce Viability Specifically in Liver Cancer Cells That Express High Levels of SALL4 by Inhibiting Oxidative Phosphorylation. Gastroenterology. https://doi.org/10.1053/j.gastro.2019.08.022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.